This article is more than 5 years old. Information may no longer be current.

VIDEO: Risuteganib meets primary outcome in phase 2 study for intermediate, dry AMD

ByPeter K. Kaiser, MD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — At the American Society of Retina Specialists meeting, Peter K. Kaiser, MD, of the Cole Eye Institute at the Cleveland Clinic, discusses phase 2 study results of risuteganib (Luminate, Allegro Ophthalmics), for the treatment of intermediate, dry AMD with some vision loss. The treatment met the study’s primary outcome at 28 weeks with 8 letters of visual acuity gained.